Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

Abstract

Purpose: Early results from the phase II MEDIOLA study (NCT02734004) in germline BRCA1- and/or BRCA2-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) showed promising efficacy and safety with olaparib plus durvalumab. We report efficacy and safety of olaparib plus durvalumab in an expansion cohort of women with gBRCAm PSROC (gBRCAm expansion doublet cohort) and two cohorts with non-gBRCAm PSROC, one of which also received bevacizumab (non-gBRCAm doublet and triplet cohorts).

Patients and Methods: In this open-label, multicenter study, PARP inhibitor-naïve patients received olaparib plus durvalumab treatment until disease progression; the non-gBRCAm triplet cohort also received bevacizumab. Primary endpoints were objective response rate (ORR; gBRCAm expansion doublet cohort), disease control rate (DCR) at 24 weeks (non-gBRCAm cohorts), and safety (all cohorts).

Results: The full analysis and safety analysis sets comprised 51, 32, and 31 patients in the gBRCAm expansion doublet, non-gBRCAm doublet, and non-gBRCAm triplet cohorts, respectively. ORR was 92.2% [95% confidence interval (CI), 81.1–97.8] in the gBRCAm expansion doublet cohort (primary endpoint); DCR at 24 weeks was 28.1% (90% CI, 15.5–43.9) in the non-gBRCAm doublet cohort (primary endpoint) and 74.2% (90% CI, 58.2–86.5) in the non-gBRCAm triplet cohort (primary endpoint). Grade ≥ 3 adverse events were reported in 47.1%, 65.6%, and 61.3% of patients in the gBRCAm expansion doublet, non-gBRCAm doublet, and non-gBRCAm triplet cohorts, respectively, most commonly anemia.

Conclusions: Olaparib plus durvalumab continued to show notable clinical activity in women with gBRCAm PSROC. Olaparib plus durvalumab with bevacizumab demonstrated encouraging clinical activity in women with non-gBRCAm PSROC. No new safety signals were identified.

People
Drew, Yvette
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Kim, Jae-Weon
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Penson, Richard T.
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
O'Malley, David M.
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Parkinson, Christine
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Roxburgh, Patricia
Author

Krebs, Matthew G. and Forster, Martin and Majem, Margarita and Peguero, Julio and Iams, Wade and Clay, Tim and Roxburgh, Patricia and Doger, Bernard and Bajaj, Pawan and Barba, Andres and Perera, Suvini and Mueller, Christian and Triebel, Frédéric (2024) Eftilagimod alpha (a soluble LAG-3 protein) combined with pembrolizumab in second-line metastatic NSCLC refractory to anti–programmed cell death protein 1/programmed death-ligand 1-based therapy: final results from a phase 2 study. JTO Clinical and Research Reports, 5 (11): 100725. ISSN 2666-3643

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Plummer, Ruth
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Im, Seock-Ah
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Imbimbo, Martina
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Ferguson, Michelle
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Rosengarten, Ora
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Steeghs, Neeltje
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Kim, Min Hwan
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Gal-Yam, Einav
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Tsoref, Daliah
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Kim, Jae-Hoon
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
You, Benoit
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
De Jonge, Maja
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Lalisang, Roy
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Gort, Eelke
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Bastian, Sara
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Meyer, Kassondra
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Feeney, Laura
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Baker, Nigel
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Ah-See, Mei-Lin
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Domchek, Susan M.
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Banerjee, Susana
Author

Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana (2024) Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clinical Cancer Research, 30 (1). pp. 50-62. ISSN 1078-0432

See full publications list
Texts
389:404
lightbox image
316636.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (531kB) | Preview
Information
Title:
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Creators:
Drew, Yvette and Kim, Jae-Weon and Penson, Richard T. and O'Malley, David M. and Parkinson, Christine and Roxburgh, Patricia and Plummer, Ruth and Im, Seock-Ah and Imbimbo, Martina and Ferguson, Michelle and Rosengarten, Ora and Steeghs, Neeltje and Kim, Min Hwan and Gal-Yam, Einav and Tsoref, Daliah and Kim, Jae-Hoon and You, Benoit and De Jonge, Maja and Lalisang, Roy and Gort, Eelke and Bastian, Sara and Meyer, Kassondra and Feeney, Laura and Baker, Nigel and Ah-See, Mei-Lin and Domchek, Susan M. and Banerjee, Susana
Identification Number:
10.1158/1078-0432.ccr-23-2249
Date:
1 January 2024
Divisions:
College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Publisher:
American Association for Cancer Research
Additional Information:
** Article version: VoR ** From Crossref journal articles via Jisc Publications Router ** History: epub 08-11-2023; issued 08-11-2023; ppub 05-01-2024. ** Licence for VoR version of this article starting on 05-01-2024: https://creativecommons.org/licenses/by-nc-nd/4.0/
Library
URI:
https://pub.demo35.eprints-hosting.org/id/eprint/389
Item Type:
Article
Depositing User:
Unnamed user with email ejo1f20@soton.ac.uk
SWORD Depositor:
Users 37347 not found.
Date Deposited:
11 Jun 2025 16:37
Revision:
12
Last Modified:
12 Jun 2025 10:02
View Item